These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36637439)

  • 1. Sodium Propionate or Sodium Butyrate Promotes Fatty Acid Oxidation in HepG2 Cells Under Oxidative Stress.
    Cook KJ; Coulter A; Keenan M; Greenway F; Losso JN
    J Med Food; 2023 Jan; 26(1):74-79. PubMed ID: 36637439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
    Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
    J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
    Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
    Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen Signals Through Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α to Reduce Oxidative Damage Associated With Diet-Induced Fatty Liver Disease.
    Besse-Patin A; Léveillé M; Oropeza D; Nguyen BN; Prat A; Estall JL
    Gastroenterology; 2017 Jan; 152(1):243-256. PubMed ID: 27658772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
    Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
    Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic SIRT1/PGC-1α pathway.
    Meng D; Yin G; Chen S; Zhang X; Yu W; Wang L; Liu H; Jiang W; Sun Y; Zhang F
    Eur J Pharmacol; 2024 Aug; 977():176737. PubMed ID: 38866362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
    Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
    Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem mass tag-based quantitative proteomics analysis reveals the effects of the α-lactalbumin peptides GINY and DQW on lipid deposition and oxidative stress in HepG2 cells.
    Chen H; Qi X; Guan K; Wang R; Li Q; Ma Y
    J Dairy Sci; 2023 Apr; 106(4):2271-2288. PubMed ID: 36797178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice.
    Fuchs CD; Radun R; Dixon ED; Mlitz V; Timelthaler G; Halilbasic E; Herac M; Jonker JW; Ronda OAHO; Tardelli M; Haemmerle G; Zimmermann R; Scharnagl H; Stojakovic T; Verkade HJ; Trauner M
    Hepatology; 2022 Jan; 75(1):125-139. PubMed ID: 34387896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
    Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
    Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidation of SIRT-1/PGC-1α-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease.
    Jiang Y; Chen D; Gong Q; Xu Q; Pan D; Lu F; Tang Q
    Lipids Health Dis; 2021 Apr; 20(1):40. PubMed ID: 33902605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of
    Mun J; Park J; Yoon HG; You Y; Choi KC; Lee YH; Kim K; Lee J; Kim OK; Jun W
    J Med Food; 2019 Dec; 22(12):1262-1270. PubMed ID: 31834842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease.
    Maruyama H; Kiyono S; Kondo T; Sekimoto T; Yokosuka O
    Int J Med Sci; 2016; 13(3):169-78. PubMed ID: 26941577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells.
    Kim MS; Sweeney TR; Shigenaga JK; Chui LG; Moser A; Grunfeld C; Feingold KR
    Metabolism; 2007 Feb; 56(2):267-79. PubMed ID: 17224343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Lipotoxic Effects of Palmitate and Oleate in Activated Human Hepatic Stellate Cells and Epithelial Hepatoma Cells.
    Hetherington AM; Sawyez CG; Zilberman E; Stoianov AM; Robson DL; Borradaile NM
    Cell Physiol Biochem; 2016; 39(4):1648-62. PubMed ID: 27626926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway.
    Zhang X; Ji R; Sun H; Peng J; Ma X; Wang C; Fu Y; Bao L; Jin Y
    Free Radic Res; 2018 Feb; 52(2):198-211. PubMed ID: 29400110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.